Immunoassay Market Overview, Key Company Prospects, Innovative Development Strategies and Forecast to 2023
Market Highlights:
The global immunoassay market size accounted for USD 18,626.7 million in 2018 and is
projected to register a CAGR of 5.9% over the forecast period.
Immunoassay is a biochemical test that relies on biochemistry to measure the
presence and concentration of an analyte (protein, lipid, nucleic acid, among
others) in solution (serum, urine, etc.) by using antibody-antigen reactions.
Some of the factors characterizing the market growth are rising R&D
expenditure in the healthcare sector, rising prevalence of chronic and
infectious diseases, increasing adoption of immunoassay, technological
advancements in immunoassay instruments and the introduction of novel automated
systems, and surging elderly population across the world. For instance, the
World Health Organization (WHO) reported that global elderly population was
841.0 million in 2013, increased to 962.3 million in 2017, which is projected
to reach more than 2.0 billion by the end of 2050. In contrast, limitations
associated with immunoassay techniques, lack of reimbursement policies in some
countries are anticipated to impede the market growth from 2019 to 2025.
Browse Full Report Details and
TOC @ https://www.marketresearchfuture.com/reports/immunoassay-market-5841
Key Players:
·
Thermo
Fisher Scientific Inc
·
F.
Hoffmann-La Roche Ltd
·
bioMérieux
SA
·
Siemens
Healthineers
·
Abbott
Laboratories
·
Becton
·
Dickinson
and Company
·
Danaher
Corporation
·
Merck
KGaA
·
Sysmex
Corporation
·
Ortho-Clinical
Diagnostics
Segmentation:
·
The
global immunoassay market has been segmented into product, technology,
indication, end user, and region.
·
By
product, the market has been segmented into reagents and kits, analyzers/instruments,
software, and services.
·
On the
basis of technology, the market has been divided into radioimmunoassay (RIA),
enzyme-linked immunosorbent assay (ELISA), enzyme-linked fluorescent assay
(ELFA), chemiluminescence immunoassay (CLIA), rapid test, and others.
·
By
indication, the global immunoassay market has been categorized into therapeutic
drug monitoring, oncology, cardiology, endocrinology, infectious diseases,
autoimmune diseases, and others.
·
Based on
end user, the market has been classified into hospitals, clinical laboratories,
blood banks, pharmaceutical and biotechnology companies, academic and research
institutes, and others.
Regional Analysis:
The global immunoassay market has been categorized
on the basis of region into the Americas, Europe, Asia-Pacific, and the Middle
East & Africa. On a regional basis, the Americas would showcase supremacy
over other regions throughout the forecast period. This is attributed to
headquartered major market participants, increasing expenditure on research and
development activities, the rising burden of chronic diseases and sophisticated
healthcare infrastructure, and growing adoption of immunoassay in the US and
Canada. For instance, as per the data published by Pharmaceutical Research and
Manufacturers of America (PhRMA), the US pharmaceutical research and
development (R&D) expenditure had grown from USD 2 million in 1980 to USD
71.4 million in 2017.
Europe would follow Americas in terms of value over
the forecast period due to flourishing pharmaceutical and biotechnology
companies, mounting adoption in diagnostic measures, and growing use of
chemiluminescent immunoassay in the UK, Germany, and France. According to the
European Federation of Pharmaceutical Industries and Associations (EFPIA), in
2016, Europe accounted for 21.5% of world pharmaceutical sales, which rose to
22.2% of global pharmaceutical sales in 2017.
The market in Asia-Pacific would register the
fastest market growth over next seven years owing to booming medical tourism,
rapid developing healthcare infrastructure, increasing geriatric population
coupled with the rising burden of chronic diseases, growing awareness about
immunoassay tests in the developing countries, such as China, India, Singapore,
and Australia. The World Health Organization (WHO) stated that noncommunicable
diseases (NCDs), mainly cardiovascular diseases (CVD), chronic respiratory
diseases, cancer, and diabetes are top killers in the South-East Asia Region,
claiming an estimated 8.5 million lives every year.
The Middle East & Africa are projected to
demonstrate a steady growth in the global immunoassay market over the forecast
period. In addition, the major market share of the region would be held by the
Middle Eastern region due to recent activity from governments in the region
approaching investors to expand the private sector in healthcare which
continues to be encouraging.
About Market Research Future:
At Market Research Future (MRFR), we
enable our customers to unravel the complexity of various industries through
our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw
Research Reports (3R), Continuous-Feed Research (CFR), and Market Research
& Consulting Services.
MRFR team have supreme objective to provide the
optimum quality market research and intelligence services to our clients. Our
market research studies by Components, Application, Logistics and market
players for global, regional, and country level market segments, enable our
clients to see more, know more, and do more, which help to answer all their
most important questions.
In order to stay updated with technology and work
process of the industry, MRFR often plans & conducts meet with the industry
experts and industrial visits for its research analyst members.
Contact:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
+1 646 845 9312
Comments
Post a Comment